Enliven Therapeutics, Inc. Common Stock (ELVN) Technical Analysis
$49.45
Market is closed - opens 7 PM, 21 Sep 2026
Insights
- Enliven Therapeutics Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
- Based on analysis of the Oscillators technical indicator, the current market trend for Enliven Therapeutics Inc. stock suggests that it is a good time to buy
- Based on analysis of the Moving Averages technical indicator, Enliven Therapeutics Inc. stock is in a downtrend↘️
- Based on analysis of the Pivot Points, the current market trend for Enliven Therapeutics Inc. stock suggests that it is a good time to sell or bad time to initiate a fresh position
Analysis Summary
Oscillators
Sell
Neutral
Buy
Moving Averages
Sell
Neutral
Buy
Pivots
Sell
Neutral
Buy
Oscillators
Name | Value | Action |
|---|---|---|
Relative Strength Index | 28.28 | Buy |
Stochastic | 8.49, 9.33 | Neutral |
Ultimate Oscillator | 24.8 | Buy |
Stochastic Relative Strength Index | 9.19, 5.06 | Buy |
Moving Average Convergence Divergence | -1.72, -0.48 | Neutral |
Moving Averages
Simple Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 54.33 | Sell |
20 | 56.95 | Buy |
50 | 56.26 | Buy |
Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 53.34 | Sell |
20 | 55.29 | Buy |
50 | 54.85 | Buy |
Volume Weighted Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 52.92 | Sell |
20 | 55.01 | Sell |
50 | 55.75 | Sell |
Double Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 50.4 | Sell |
20 | 53.46 | Sell |
50 | 57.82 | Buy |
Triple Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 49.03 | Sell |
20 | 50.79 | Sell |
50 | 57.05 | Sell |
Pivot
Pivot | Value |
|---|---|
Resistance L3 | 54.12 |
Resistance L2 | 52.97 |
Resistance L1 | 51.61 |
Pivot Point | 50.46 |
Support L1 | 49.1 |
Support L2 | 47.95 |
Support L3 | 46.59 |
*Disclaimer: The content present here is for informational purposes only, you should not construe any such information or other material as investment advisory.